1 Min Read
April 3 (Reuters) - Versartis Inc:
* Three-year Vertical/Vista study results support selection of 3.5 mg/kg twice-monthly dose regimen for phase 3 Velocity trial underway Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.